Product
TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
1 clinical trial
2 indications
Indication
HIV InfectionsIndication
Hepatitis B Virus CoinfectionClinical trial
Interventional, Multicenter, Open-label, Randomized, Non-comparative Trial Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV VirusesStatus: Not yet recruiting, Estimated PCD: 2027-02-28